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Several recent studies have reported a 40–50% lower colorectal
cancer risk in people who are continuously taking aspirin or other
non-steroidal anti-inflammatory drugs (NSAIDs) (Thun et al,
1991; Marnett, 1992; Thun et al, 1993; Giovannucci et al, 1994,
1995; Marnett et al, 1995), suggesting that these drugs may be
useful in the chemoprevention of colorectal cancer. The mecha-
nism by which NSAIDs prevent colorectal carcinogenesis is not
clearly known, but one possibility involves inhibition of cyclo-
oxygenase (COX). COX is a key enzyme in the conversion of
arachidonic acid to prostaglandins, and two isoforms have been
identified, namely COX-1 and COX-2. COX-1 is constitutively
expressed in most cells and tissues, including normal intestinal and
gastric mucosa (Williams and DuBois, 1996). On the other hand,
COX-2 is induced by a variety of agents including cytokines,
growth factors and tumour promoters; COX-2 expression is
elevated in inflammatory cells and sites of inflammation (Kujubu
et al, 1991; O’Banion et al, 1991; Jones et al, 1993; DuBois et al,
1994; Xie and Hershman, 1995). Multiple studies have shown that
COX-2 is expressed at high levels in 80–90% of colorectal adeno-
carcinomas (Eberhart et al, 1994; Kargman et al, 1995; Sano et al,
1995), and selective inhibition of COX-2 reduces colorectal
tumorigenesis in different models of carcinogenesis (Oshima et al,
1996; Reddy et al, 1996; Kawamori et al, 1998). Thus, COX-2 has
been thought to play a causal role in colorectal tumorigenesis.
In this study, the inhibitory effect of a selective COX-2
inhibitor, JTE-522, on haematogeneous metastasis was examined
in a mouse model of lung metastasis of colorectal cancer.
MATERIALS AND METHODS
Preparation of JTE-522
In vivo studies, the selective COX-2 inhibitor, JTE-522
(Matsushita et al, 1997), was suspended in vehicle of 0.5%
carboxymethyl cellulose sodium salt (CMC). CMC was obtained
from Wako Life Science Reagents (Osaka, Japan). For in vitro
studies, JTE-522 was dissolved in dimethyl sulphoxide (DMSO)
(Sigma, Watford, UK).
Animals
Female BALB/c mice were purchased from Oriental Yeast Co.,
Ltd (Tokyo, Japan). Seven-week-old mice weighing 20 g were
used in all experiments.
Murine colon cancer
Subclones of the murine colon cancer cell line, colon-26, were
used. One subclone (clone 5) (Fujimoto-Ouchi et al, 1995) had
low COX-2 expression. Another subclone, clone P, established in
our laboratory highly expressed COX-2. Both cells were cultured
in vitro in RPMI-1640 containing 5% fetal calf serum and 1%
antibody (complete medium).
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Western blotting
For the analysis of COX-2 expression, cells were seeded in
100mm plastic dishes and grown to subconfluence in complete
medium. The medium was removed, and cell monolayers were
washed three times with phosphate-buffered saline and homoge-
nized in Tris-saline (50mMTris-HCl (pH 7.6), 150mMsodium
chloride) containing various protease inhibitors (1mMEGTA,
0.1mM diisopropyl fluorophosphate, 0.5mM phenylmethyl-
sulphonyl fluoride, 1mg ml–1 Na-p-tosyl-L-lysine chloromethyl
ketone, 1mg ml–1 antipain, 0.1mg ml–1 pepstain, 1mg ml–1 of
leupeptin). The homogenate was spun at 100000rpm for 15min
on a TL-100 rotor (Beckman, CA, USA) and the clear supernatant
was used as the cell cytosolic protein fraction. The protein concen-
tration of the supernatant was determined using the Bio-Rad DC
Protein Assay (Bio-Rad, CA, USA).
Sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS–PAGE) was performed as described previously (Hasegawa
et al, 1990) using a Laemmli buffer system and 10% poly-
acrylamide resolving slab gels. Proteins were then transferred
electrophoretically to polyvinylidine difluoride (PVDF,
Immobilon P; Millipore, Bedford, MA, USA). The PVDF
membrane was first equilibrated in transfer buffer (192mM
glycine, 25mMTris, 20% methanol, pH 8.3). The cell cytosolic
fraction samples were reduced with 2% 2-mercaptoethanol 
(2-ME). Blotting was carried out at 150V for 1h (4°C). After
blotting, the remaining reactive sites of the PVDF membrane were
blocked by incubating the sheets in TBS containing 3% gelatin.
The same buffer containing 10% calf serum (CS) was used to
dilute either antisera or purified antibodies. The membrane strips
were incubated with the goat anti-COX-2 antibody (Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA) overnight (16–20h) at
ambient temperature on a shaker, washed three times for 15min
and incubated with a 1:500 dilution of biotinylated anti-goat IgG
(Vector Laboratories, Inc., Burlingame, CA, USA). After 1h, the
strips were washed an additional three times and then incubated
with a freshly prepared avidin–biotin complex (ABCkit, Vector)
solution for 30min. After washing three times, colour develop-
ment was carried out with a solution of 4-chloro-1-naphthol.
In vitro proliferation assay
The two subclones of colon-26 were seeded at 8 ´104 per well in
96-well flat-bottomed plates in triplicate in RPMI-1640 medium
containing 0.1% bovine serum albumin (BSA) and allowed to
adhere overnight. Then medium containing differing concentra-
tions of JTE-522 diluted in DMSO was added at final concentra-
tions of 0, 10, 25 and 50mM. After 48h, the proliferative activity
was determined by MTS assay (CellTilter 96TM Non-Radioactive
Cell Proliferation Assay, Promega Corporation, Madison, WI,
USA), which monitors the number of viable cells. After 4h in
medium containing MTS, the conversion of MTS to formazan was
measured in a plate reader at 490nm. As JTE is used dissolved in
DMSO, and different concentrations of DMSO are used for
different doses of JTE, the proliferation inhibition curves
according to the dose of JTE were expressed as a ratio between the
value obtained with JTE and that obtained with DMSO only. IC50s
were determined from the curves.
Measurement of apoptosis by DNA fragmentation
Apoptosis was measured by the level of fragmented DNA
contained in cell lysates following treatment with JTE-522. The
method for measuring fragmented DNA used a commercially
available photometric enzyme-immunoassay kit (Cell Death
Detection ELISAPLUS; Boehringer-Mannheim, Mannheim,
Germany). The immunoassay utilizes mouse monoclonal anti-
bodies directed against DNA and histones, respectively, which
allows the determination of mononucleosomes and oligonucleo-
somes in the soluble fraction of cell lysates. The two subclones of
colon-26 were cultured in 10-cm2 dishes in complete medium and
allowed to grow to subconfluence. Then the medium was removed
and 0.1% BSA–RPMI-1640 containing JTE-522 diluted in DMSO
was added at a final concentration of 100mM(JTE group). To the
control group, only DMSO was added. After 24h of treatment,
both floating and attached cells were collected, then lysed and
assayed for fragmented DNA according to the protocol specified
by the manufacturer. Absorbance was determined by absorption
(405–490nm) using a Bio-Rad microplate reader (Bio-Rad).
Gelatin zymography assay
To investigate the effect of JTE-522 on the production of matrix
metalloproteinases, gelatin zymography was performed as
described (Kato et al, 1995), with some modifications. Briefly, the
two subclones of colon-26 were treated with JTE-522 (0 and
50mM) in RPMI-1640 medium containing 0.1% BSA for 24h.
Then cells were harvested by trypsinization, washed 3 times in
PBS, and 1 ´107 cells were suspended in serum-free DMEM: F12
(1:1 ratio) medium and incubated for another 5h. The cell super-
natants were collected, centrifuged to eliminate the contaminating
cells, and then concentrated approximately 25 times in a centricon
concentrator 10 (Amicon, Inc., Beverly, MA, USA) by centrifuga-
tion. The samples were then subjected to SDS-PAGE in 10%
acrylamide gels containing 0.1% gelatin. The gels were washed in
a 2% Triton X-100 solution for 1h at room temperature, transfered
to the incubation buffer and incubated overnight at room tempera-
ture to allow the MMPs to degrade gelatin. The gels were stained
for 30min with Coomassie blue for visualization of the MMPs.
Murine lung metastasis of colon cancer model
Mice were divided into two groups: control group (n= 6) and JTE
group (n= 6). Mice in the JTE group received 0.2mg JTE-522
suspended in 20ml 0.5% CMC intraperitoneally (i.p.) and those in
the control group received only 20ml 0.5% CMC i.p., every day
from 1 day prior to cancer cell injection. For both groups, a single
cell suspension of the colon-26 subclones in Hanks’ solution was
injected into the tail vein of BALB/c mice (5 ´104 cells per
mouse). Sixteen days after injection, the mice were sacrificed, the
lungs were removed, flushed with India ink, and fixed with
Fekete’s solution. Lung metastasis was evaluated macroscopi-
cally: the number of metastatic nodules was counted and the lungs
were weighed.
Assay of colon cancer cell adhesion to lung
Mice were divided into two groups: control group (n= 8) and JTE
group (n= 8). Mice in the JTE group received 0.2mg JTE-522
suspended in 20ml 0.5% CMC i.p. and those in the control group
received only the vehicle, once a day from the day prior to cancer
cell injection.
Clone P cells were labelled with 200mCi sodium [51Cr]
chromate (Du, Pont/NEN Research Products)(1 ´107 cells)1276 S Tomozawa et al
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for 1 h, washed three times in complete medium, suspended in
Hanks’ solution, and injected into the tail vein of the BALB/c mice
(5 ´ 104 cells per mouse).
Twenty hours after injection of cancer cells, mice were sacri-
ficed, the lungs removed, and 51Cr-release from the lungs was
measured in a g-counter.
Statistical analysis
All results are expressed as mean ± s.d. and were analysed by two-
tailed Student’s t-test. Differences were considered statistically
significant at P < 0.05.
RESULTS
Expression of COX-2 in subclones
Western blotting analysis showed that COX-2 is constitutively
expressed in colon-26 cell line. Clone P established in our labora-
tory expressed a high level of COX-2 whereas clone 5 expressed a
relatively low level (Figure 1).
JTE-522 inhibits colon cancer cell proliferation in vitro
The effect of JTE-522 on colon cancer cell proliferation activity
was measured by the MTS method (Figure 2). JTE-522 showed a
dose-dependent inhibitory effect on the proliferation of both
subclones. However, the growth inhibitory effect on clone P was
greater than that for clone 5. IC50s were determined from
dose–response curves of the JTE-522 concentration versus
proliferative activity. IC50s were 41.5 ± 0.6 mM and 150.0 ± 1.7 mM
for clones P and 5 respectively. These results are consistent with
the level of COX-2 expression.
JTE-522 induces colon cancer cell apoptosis in vitro
Figure 3 shows the effect of JTE-522 (100 mM) on colon cancer
cell apoptosis measured by Cell Death Detection ELISAPLUS.
COX-2
Clone 5 Clone P
Colon-26
Figure 1 Western blotting analysis of COX-2 expression levels in colon-26
subclones. The cytosolic protein fraction was obtained by cell
homogenization, and after adjustment for protein concentration, the
samples were subjected to SDS-PAGE. Bands indicating COX-2 protein
were detected at Mr 69 000. Clone P expressed a high level of COX-2 and
clone 5 a low level
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Figure 2 Proliferation activity (% control) of colon-26 subclones assessed
by MTS dehydrogenase activity in cell culture in the presence and absence
of various concentrations of JTE-522. Results are expressed as the mean of
three different experiments, and the s.d. values are so small that were not
expressed. IC50 determined from dose–response curves were 41.5 ± 0.6 mM
and 150.0 ± 1.7 mm for clone P and 5 respectively. The inhibitory effect of
JTE-522 was more pronounced in clone P
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Figure 3 Detection of apoptosis by measurement of DNA fragmentation
in colon-26 subclones after treatment with 100 mM JTE-522 for 24 h. The
vertical axis shows the optical density at 405–490 nm, which represents the
levels of apoptosis detected in clone P (left) and clone 5 (right) after
treatment with JTE-522. Clone P showed an approximately sevenfold
increase of apoptotic cells in the treated cells compared to control cells.
This difference was statistically significant (P < 0.01). In clone 5, JTE-522
treatment caused a small increase in apoptosis, but without statistical
significance
Control JTE
Clone 5
Control JTE
Clone P
MMP-9
MMP-2
MMP-1
Figure 4 Gelatin zymography of MMPs secreted into the cell culture
medium by colon-26 subclones. Lanes 1 and 3 show the MMPs produced by
clones 5 and P, respectively, without JTE treatment and in lanes 2 and 4,
following treatment with JTE-522 for 24 h (50 mM). Clone P produced high
levels of MMP-9 and small levels of MMP-1. JTE treatment resulted in
decreases in the production of both MMPs. Clone 5 produced high levels of
MMP-1 and low levels of MMP-9 and MMP-2. JTE-522 treatment did not
decrease MMP production, but even resulted in small increases in the
production of all MMPsInhibition of colon cancer metastasis by a selective COX-2 inhibitor 1277
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Treatment of clone P with JTE-522 (100 mM) for 24 h significantly
increased the level of fragmented DNA approximately sevenfold
(0.068 ± 0.013 in control group, 0.460 ± 0.012 in JTE group,
P < 0.05). On the other hand, treatment of clone 5 did not
significantly induce apoptosis (0.134 ± 0.018 in control group,
0.191  ± 0.005 in JTE group, P > 0.05). These results are consistent
with the COX-2 level and the results of the proliferation assay.
JTE-522 reduces the levels of MMPs
As shown in Figure 4, colon-26 clone P produced high levels of
MMP-9 (92 kDa) and also low levels of MMP-1 (52 kDa). JTE-
522 treatment resulted in decreased production of both MMP-9,
and MMP-1 (lanes 3, 4). Differently, clone 5 produced high levels
of MMP-1 and low levels of MMP-9 and MMP-2 (72 kDa). JTE-
522 treatment had little effect, or even resulted in a small increase
in the production of MMPs (lanes 1, 2). These results suggest that
JTE-522 treatment induces decreases in the invasive potential of
clone P by down-regulating the production of MMPs.
Lung metastasis
In Figures 5 and 6, the effect of JTE-522 on the number of lung
metastatic nodules and the lung weight are shown for both clones.
No significant side-effects of JTE-522 administration were
observed. Figure 6 shows the representative lungs from mice of
the control and treatment groups injected with clone P (control
group n = 6 vs JTE group n = 6). In mice injected with clone P,
treatment with JTE-522 significantly reduced the number of
metastatic nodules (73.2 ± 26.7 in control group, 24.5 ± 24.7 in
JTE group, P < 0.05) and the lung weight (1011 ± 102.2 mg in the
control group, 717.8 ± 96.8 mg in JTE group, P < 0.05) (Figure 5).
In contrast, in mice injected with clone 5, there was little differ-
ence between the two groups, although the average number of
metastatic nodules (27.3 ± 16.8 in control group, 23.8 ± 21.3 in
JTE group) and that of lung weight (766.7 ± 41.7 mg in control
group, 730.2 ± 43.2 mg in JTE group) were lower in the JTE group
(Figure 6). In general, clone 5 had lower metastatic potential than
clone P. These results are also consistent with those of the in vitro
experiments.
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Figure 5 Number of metastatic nodules (left) and the lung weight (right) in
the control and JTE-522-treated groups of mice injected with colon-26 clone
P. JTE-522 treatment significantly reduced the number and size of metastatic
nodules as well as the lung weight (P < 0.05)
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Figure 6 Number of metastatic nodules (left) and lung weight (right) in the
control and JTE-522-treated groups of mice injected with colon-26 clone 5.
JTE-522 treatment showed a slight tendency to cause a reduced number of
metastatic nodules as well as lung weight, but without statistical significance
Figure 7 Representative lungs of mice injected with colon-26 clone P in the
control and JTE-522-treated groups. Lungs were injected with India ink and
the normal lung parenchyma was stained black, facilitating the visualization
of metastatic nodules. In the control group a large number of metastatic
nodules were observed with little normal lung parenchyma between them.
However, in the treated group, a very small number of nodules were seen
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Figure 8 51Cr release from the lungs of the mice injected with 51Cr-labelled
clone P cells measured in a g-counter (control group n = 8 vs JTE group
n = 8). No significant difference was found (P > 0.05)1278 S Tomozawa et al
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Effect of JTE-522 on colon cancer cell adhesion to lung
in vivo
Figure 8 shows 51Cr release from the lungs of the mice injected
with 51Cr-labelled clone P cells (control group n = 8 vs JTE group
n = 8). No significant difference was recognized between
the two groups (7284.4 ± 2308.1 cpm in the control group and
7870.5 ± 796.6 cpm in the JTE group).
DISCUSSION
NSAIDs have been reported to reduce colorectal cancer risk (Thun
et al, 1991, 1993; Marnett, 1992, 1995; Giovannucci et al, 1994,
1995) and are suggested to act as cancer-preventive agents,
inhibiting both isoforms of cyclooxygenase, COX-1 and COX-2.
COX-1 is constitutively expressed in most normal tissues and
mediates the synthesis of prostaglandins for normal physiological
functions (Williams and DuBois, 1996). On the other hand, COX-
2 is not detectable in most tissues but is induced by cytokines,
growth factors, oncogenes, serum and tumour promoters (Kujubu
et al, 1991; O’Banion et al, 1991; Jones et al, 1993; DuBois et al,
1994; Xie and Hershman, 1995). Recently, several studies have
reported that COX-2 is up-regulated in most colorectal adeno-
carcinomas (Eberhart et al, 1994; Kargman et al, 1995; Sano et al,
1995). In a separate study, SC-58635, a selective inhibitor of
COX-2, reduced the formation of aberrant crypt foci and inhibited
both of incidence and multiplicity of colon tumours in the
intestines of azoxymethane-treated rats (Reddy et al, 1996;
Kawamori et al, 1998). A null mutation of COX-2 caused a
marked reduction in the number and size of intestinal polyps in a
murine model of FAP (familial adenomatous polyposis), APCs s716
knockout mice (Oshima et al, 1996). These results indicate that
selective COX-2 inhibitor could be a novel agent for the treatment
of colorectal tumorigenesis.
Recently, it has been reported that in nude mice, selective inhi-
bition of COX-2 by SC-58125 reduced growth of a human colon
cancer cell, HCA-7, expressing high levels of COX-2, but it did
not reduce the growth of HCT-116 cells lacking COX-2 protein
(Sheng et al, 1997). These results indicate that there may be a rela-
tionship between cancer growth and COX-2. Another recent report
demonstrated that human colon cancer (Caco-2) cells permanently
transfected with a COX-2 expression vector acquired increased
invasiveness, showing elevated activation of matrix metallo-
proteinase-2 (MMP-2) and increased RNA level for membrane-
type matrix metalloproteinase-1 (MT-MMP-1) (Tsuji et al, 1997).
These results suggest that constitutive expression of COX-2 can
increase the metastatic potential of colorectal cancer cells.
Therefore, it can be proposed that a selective COX-2 inhibitor may
suppress metastasis of colon cancer.
In this study, we investigated the potential of a selective COX-2
inhibitor, JTE-522, as an inhibitor of haematogenous metastasis of
colorectal cancer, using a murine model of lung metastasis, and
found that JTE-522 inhibited lung metastasis of clone P of colon-
26, which expressed a high level of COX-2, and did not have a
significant inhibitory effect on clone 5, which expressed a low
level.
One of the mechanisms of the anti-metastatic effect of JTE-522
may be inhibition of colon cancer cell growth, because JTE-522
inhibited the proliferation of colon cancer cells in vitro in a dose-
dependent manner. Recently, it has been reported that NS-
398, another selective COX-2 inhibitor, induced apoptosis and
suppressed the proliferation of colon cancer cells (Elder et al,
1997; Hara et al, 1997). In this study, we also demonstrated that
JTE-522 induced apoptosis of colon cancer cells, and the induction
of apoptosis is probably one of the mechanisms of inhibition of
colon cancer cell proliferation. Cyclooxygenase inhibitors are
known to induce G1 arrest of cell in the cell cycle (Piazza et al,
1997), and we also confirmed that JTE-522 also induced G1 arrest
in colon cancer cell lines (data not shown). Consequently, JTE-522
probably induces apoptosis in cells in the G1 phase, and therefore
clone 5 that is a slower grower may be less affected than clone P.
Another of the mechanisms of the anti-metastatic effect of JTE-
522 may be reduction of the levels of MMPs, once COX-2 trans-
fection to colon cancer cells increased the production of MMPs
(Tsuji et al, 1997), and consequent invasiveness. MMPs are
enzymes that are essential for cancer cells to invade and entry into
and out of blood or lymphatic vessels (intravasation, extravasa-
tion) (Chamber and Matrisian, 1997). JTE-522 treatment of clone
P markedly reduced the production of MMPs, while in clone 5 it
resulted in slightly increased production.
Haematogenous metastasis of colorectal cancer develops
through a complicated process: cancer cells detach from the
primary site and reach the vasculature by proteolytic cleavage of
the surrounding interstitial tissues. Then the cells reach the
secondary sites by adhesion to and transmigration through the
endothelial cell layer and invasion of the secondary organ, and
they proliferate at secondary sites by induction of angiogenesis
(Liotta et al, 1986). Inhibition of lung metastasis by JTE-522 may
be the consequence of decreased capacity of cancer cells to
extravasate from blood vessels and invade the lung, associated
with decreased proliferative activity at the lung due to induction of
apoptotic death of cancer cells. We also demonstrated that JTE-
522 had little effect on the adhesion of colon cancer cells to
endothelial cells, another possible mechanism of inhibition of
metastasis.
Tumour growth and metastasis require the development of new
vessels, i.e. angiogenesis (Folkman, 1990; Mahadevan and Hart,
1990; Horak et al, 1992). Recently, both stimulatory and inhibitory
factors of angiogenesis have been found, but it is still unclear
whether there is a relationship between a selective COX-2
inhibitor and angiogenesis of colorectal cancer. Prostaglandin E2, a
product of COX, has been reported to enhance angiogenesis in
vivo (Ziche et al, 1982), and recently it has been reported that
diclofenac (a NSAID), an inhibitor of both COX-1 and COX-2,
reduced angiogenesis of colon-26 tumours (Seed et al, 1997), and
that in rats a selective COX-2 inhibitor, NS-398, inhibited angio-
genesis of sponge granuloma tissues (Majima et al, 1997). In
another recent report, COX-2 was reported to modulate the
production of angiogenic factors by colon cancer cells, while
COX-1 was associated with angiogenesis regulation in endothelial
cells (Tsujii et al, 1998). These results suggest that one mechanism
by which a selective COX-2 inhibitor inhibits colorectal tumori-
genesis and metastasis may be the suppression of angiogenesis.
We also found that although COX-2 expression was found in
endothelial cells and JTE-522 inhibited their proliferation in in
vitro studies, this inhibitory effect was not as marked as in colon-
26 cells (data not shown).
We did not investigate the synthesis of prostaglandins by the
subclones of colon-26 nor the effect of JTE-522 on prostaglandin
synthesis, but there are many reports on the relation between
prostaglandin synthesis and COX-2 in colon cancer cells. Sheng
et al (1997) reported that SC58125, another selective COX-2inhibitor, inhibited prostaglandin E2 production in a human colon
cancer cell line, HCA-7, that maintained constitutive COX-2
expression and produced significant prostaglandin E2. Moreover,
Tsuji et al (1997) demonstrated an eightfold increase in PGE2
synthesis by COX-2 transfected cells compared to the control
Caco-2, a human colon cancer cell line.
In this study, we demonstrated that JTE-522 inhibited metastasis
of colon cancer cells that highly expressed COX-2. To our knowl-
edge, this is the first report on the effect of a selective COX-2
inhibitor on cancer metastasis.
The selective COX-2 inhibitor, JTE-522, used in our study is a
novel agent that has been recently developed. Consequently, little
is known on its exact mechanism of action, and further studies are
necessary to investigate its effects in the various steps of the
metastatic process.
In conclusion, selective COX-2 inhibitors may be a novel class of
therapeutic agents, not only for colorectal tumorigenesis, but also
for prevention of haematogenous metastasis of colorectal cancer.
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